EAC 2023 Update in Allergy, Asthma & Immunology

June 1, 2023 to June 4, 2023

The 2023 EAC activity will provide conference attendees with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology.  In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases.  By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning diagnostic and treatment strategies for patients.  Topics of discussion will include immunodeficiency, pediatric asthma, biologics for allergic diseases, allergy immunotherapy, mastocytosis, asthma, atopic dermatitis, HAE, and PIDD.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 15.50 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from BioCryst and Stallergenes Greer.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Outline an endotype, phenotype, and guideline-based approach to the treatment of asthma
  • Diagnose and manage hereditary angioedema
  • Discuss current and future allergy immunotherapy treatment options for respiratory allergies
  • Outline an approach to the use of biologics for allergic diseases, including asthma, chronic urticaria, and atopic dermatitis
  • Evaluate for potential immunodeficiency
  • Discuss therapeutic options for the management of peanut allergy
  • Diagnose and manage patients with mast cell disorders
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance
  • 15.50 CBRN
Course opens: 
06/01/2023
Course expires: 
06/01/2024
Event starts: 
06/01/2023 - 3:45pm CDT
Event ends: 
06/04/2023 - 10:00am CDT
Add to calendar: 
Rating: 
0

Agenda
Eastern Allergy Conference
Palm Beach FL
June 1-4, 2023

Thursday, June 1

3:45 – 4:05    Updates from the 2023 anaphylaxis practice parameter
            David Lang, MD
4:05– 4:15    Q & A

4:15 – 5:25    PBL: A 26-year-old woman with repeated episodes of anaphylaxis
            Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD
            Leonard Bacharier, MD, Sally Bailey, MD

5:25 – 5:40    PBL wrap up
            Mariana Castells, MD

5:40 – 6:15    Diagnose and differentiate mast cell disorders
            Mariana Castells, MD

6:15 – 6:30     Q & A

Friday, June 2

7:45 – 8:15    Peanut allergy update
            Panida Sriaroon, MD

8:15 – 8:45    Treatment approaches for non-Th2 asthma
            Mario Castro, MD

8:45 – 8:55    Q & A

8:55 – 10:15    PBL: An 8-year-old boy with frequent ED visits for asthma
            Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD,
            Leonard Bacharier, MD, Dana Wallace, MD

10:15 – 11:00     Coffee Break

11:00 – 11:30    Biomarkers and biologics in the management of pediatric severe asthma
            Leonard Bacharier, MD

11:30 – 12:00    The role of viral infections in asthma exacerbations
            Mario Castro, MD

12:00 – 12:15    Q & A

1:15 – 1:45    Integrative medicine and allergy immunology
            Maeve O’Connor, MD

1:45 – 2:30    Biologics and JAK inhibitor Jeopardy Challenge (in allergic diseases)
            David Lang, MD    

2:30 – 3:00    The PANDAS/PANS disorders:  Is it time for more Allergist-Immunologist to get involved?
            Joseph Bellanti, MD

3:00 – 3:15    Q & A

Saturday, June 3

7:45 – 8:15    Chronic cough update
            Dana Wallace, MD

8:15 – 8:45    The role of allergy in EoE
            Scott Commins, MD

8:45 – 8:55    Q & A

8:55 – 10:15    PBL: A 35-year-old man with recurrent pneumonia
            Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD
            Dana Wallace, MD, Maeve O’Connor, MD

10:15 – 11:00     Coffee Break

11:00 – 11:25    Best test options for the evaluation of suspected primary immunodeficiency
            Lisa Forbes Satter, MD

11:25 – 11:50    Non-infectious complications of CVID
            Manish Butte, MD

11:50 – 12:15    An allergist guide to using genetic testing the diagnosis and management of immunodeficiency
            Lisa Forbes Satter, MD

12:15 – 12:30    Q & A

1:25 – 1:55    Advances in the identification of patients with immunodeficiency
            Manish Butte, MD

1:55 – 2:25    Update on angioedema with normal labs
            Mark Riedl, MD

2:25 – 2:45    Q & A

Sunday, June 4

8:15 – 8:45    Immunotherapy with fungal extracts
            Hal Nelson, MD

8:45 – 9:15    Alpha-Gal syndrome
            Scott Commins, MD

9:15 – 9:45    Expanding and diversifying your allergy immunology practice
            Melinda Rathkopf, MD

9:45 – 10:00    Q & A


 

 

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All relevant financial relationships with ineligible companies have been mitigated.

The individuals listed below disclose the following financial relationships:

Leonard Bacharier, MD – Speaker
Speaker: Sanofi and Regeneron
Advisor: Sanofi and Regeneron, GSK, Genentech/ Novartis, AstraZeneca, Avillion, DBV Technologies, OM Pharma, Vertex,  Recludix, Kinaset
Royalties: Elsevier

Sally Bailey, MD – Speaker
Speaker: ALK, OptiNose, Sanofi and Regeneron
Advisor: ALK

Don Bukstein, MD - Speaker
Speaker: Sanofi and Regeneron, AstraZeneca
Advisor: SDM Central

Manish Butte, MD – Speaker
Advisor: CSL Behring, Grifols, ADMA, Horizon
Speaker: CSL Behring, Grifols, ADMA
Researcher: Takeda

Mario Castro, MD – Speaker
Speaker: Amgen, AstraZeneca, Genentech, SGK, Regeneron, Sanofi, Teva
Consultant: Pulmatrix, Arrowhead Pharmaceuticals, Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicine, GSK
Independent Contractor: AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Sanofi-Aventis

Scott Commins, MD – Speaker    
Speaker: Genentech
Royalties: Up-to-Date
Researcher: Revivicor, Inc

William Corrao, MD – Planner, Moderator
Speaker: GSK

Ray Davis, MD – Speaker
Consultant: Teva, Takeda, Regeneron, Sanofi

David M Lang, MD – Speaker
Speaker: Sanofi and Regeneron, AstraZeneca
Researcher: Sanofi and Regeneron, Genentech, Novartis
Consultant: Genentech, Novartis, Blueprint

Harold Nelson, MD – Speaker
Speaker: ALK-Abello
Consultant: Everest

Maeve O’Connor, MD – Speaker
Speaker: GSK, BioCryst, Blueprint, Pharming
Consultant: GSK, Blueprint, Pharming
Advisor: CSL Behring, Blueprint

Melinda M Rathkopf, MD – Speaker
Speaker: Teva

Marc Riedl, MD – Speaker
Speaker: CSL Behring, Grifols, Pharming, Takeda
Consultant: Astria, BioCryst, BioMarin, CSL Behring, Cycle Pharma, Intellia, Ipsen, Kalvista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi and Regeneron, Spark, Takeda
Researcher: BioCryst, BioMarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda

Lisa Forbes Satter, MD – Speaker
Advisor: Grifols, Enzyvant, ADMA, Incyte, Takeda
Speaker: Grifols, Takeda

Panida Sriaroon, MD – Speaker
Advisor: Genentech
Speaker: Genentech, Aimmune
Researcher: Regeneron, Novartis
Consultant: Genentech

Robert Settipane, MD – Planner/Moderator
Independent Contractor: AstraZeneca, GSK, Regeneron, Teva

Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer
Advisor: AbbVie, Amgen, Boehringer Ingelheim, DBV, GSK, Pfizer, Aimmune
Speaker: AbbVie, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Regeneron, Sanofi, Takeda
Independent Contractor: AstraZeneca, GSK, Regeneron, Teva

Dana Wallace, MD – Speaker
Speaker: Sanofi
Consultant: AbbVie, Bryn

The following have no relevant financial relationships with ineligible companies to disclose:

Joseph Bellanti, MD – Planner/Speaker

Mariana Castells, MD – Speaker

William Greisner, III, MD – Planner/Moderator/Reviewer

Ginny Loiselle – Coordinator

Katelyn Loiselle, BSN, RN – Planner

Michael Slaughter, MD – Planner/Moderator

Kelli Wilson – Planner

Available Credit

  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance
  • 15.50 CBRN
Please login or create an account to take this course.